

# Simon J Bowman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2337462/publications.pdf>

Version: 2024-02-01

90  
papers

8,048  
citations

66343

42  
h-index

58581

82  
g-index

93  
all docs

93  
docs citations

93  
times ranked

6396  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet</i> , The, 2022, 399, 161-171.	13.7	72
2	History of tonsillectomy is associated with glandular inflammation in Sjögren's disease. <i>Rheumatology</i> , 2022, , .	1.9	0
3	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 979-989.	0.9	27
4	Immunofibroblasts regulate LT $\alpha$ 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	4.4	8
5	Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature. <i>RMD Open</i> , 2022, 8, e002119.	3.8	1
6	Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers. <i>BMJ Open</i> , 2022, 12, e055208.	1.9	0
7	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 1364-1375.	1.9	26
8	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
9	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology</i> , The, 2021, 3, e553-e562.	3.9	31
10	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 706737.	4.8	8
11	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
12	Outcome Measures in Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020, 72, 134-149.	3.4	6
13	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1588-1599.	0.9	83
14	Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2020, 40, 541-548.	3.0	22
15	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2020, 2, e142-e152.	3.9	68
16	Mediterranean diet and risk of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 216-221.	0.8	4
17	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. <i>Rheumatology International</i> , 2019, 39, 1867-1873.	3.0	35
18	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53

#	ARTICLE	IF	CITATIONS
19	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
20	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13490-13497.	7.1	115
21	Disease activity and patient reported outcome measures in Sjögren's " what are the best tools to evaluate?. <i>Rheumatology</i> , 2019, , .	1.9	7
22	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e000885.	3.8	14
23	FRIO652...SERUM CXCL13 LEVELS ARE ASSOCIATED WITH LYMPHOMA RISK AND LYMPHOMA OCCURRENCE IN PRIMARY SJÖGREN'S SYNDROME. , 2019, , .		1
24	SPO190...2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÖGREN'S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
25	Clinical Aspects of Sjögren's. , 2019, , 566-578.		0
26	Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 249-260.	0.9	33
27	B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt?. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 217-224.	0.8	7
28	Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. <i>Rheumatology</i> , 2018, 57, 921-930.	1.9	102
29	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	5.6	49
30	Mixed-Method Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2018, 70, 1064-1073.	3.4	15
31	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 412-416.	0.9	86
32	B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. <i>Rheumatology</i> , 2018, 57, 1222-1227.	1.9	23
33	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1161-1168.	0.9	200
34	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 9-16.	0.9	959
35	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 1440-1450.	5.6	194
36	The healthcare quality improvement partnership national early arthritis audit. <i>Rheumatology</i> , 2017, 56, 171-172.	1.9	0

#	ARTICLE	IF	CITATIONS
37	A new MHC-linked susceptibility locus for primary Sjögren's syndrome: MICA. <i>Human Molecular Genetics</i> , 2017, 26, 2565-2576.	2.9	22
38	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. <i>RMD Open</i> , 2017, 3, e000364.	3.8	87
39	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , 2017, 56, e24-e48.	1.9	33
40	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	3.5	60
41	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
42	The national clinical audit for rheumatoid and early inflammatory arthritis. <i>Clinical Medicine</i> , 2016, 16, 500-501.	1.9	0
43	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	3.8	77
44	Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sjögren's syndrome: a pilot study. <i>Journal of Clinical Periodontology</i> , 2016, 43, 26-33.	4.9	29
45	Sjögren syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16047.	30.5	511
46	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
47	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
48	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 780-783.	0.9	40
49	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
50	A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1645-1650.	0.9	85
51	IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11024-11029.	7.1	173
52	Stratifying primary Sjögren's syndrome: killers in the balance?. <i>Arthritis Research and Therapy</i> , 2015, 17, 351.	3.5	4
53	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. <i>Rheumatology</i> , 2015, 54, 655-659.	1.9	22
54	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2015, 55, kev373.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
56	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	2.9	74
57	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , 2015, 54, 836-843.	1.9	92
58	The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjögren's Syndrome. <i>Swiss Medical Weekly</i> , 2015, 145, w14168.	1.6	26
59	The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren's Syndrome. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 21.	1.9	43
60	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77
61	Rheumatoid Arthritis is Associated with IgG Antibodies to Human Endogenous Retrovirus Gag Matrix: A Potential Pathogenic Mechanism of Disease?. <i>Journal of Rheumatology</i> , 2014, 41, 1952-1960.	2.0	29
62	Classification criteria for Sjogren's syndrome: nothing ever stands still!. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1-2.	0.9	54
63	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
64	Association of Genes in the NF- $\kappa$ B Pathway with Antibody-Positive Primary Sjögren's Syndrome. <i>Scandinavian Journal of Immunology</i> , 2013, 78, 447-454.	2.7	45
65	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. <i>Nature Genetics</i> , 2013, 45, 1284-1292.	21.4	427
66	Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 476-478.	0.9	90
67	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1973-1979.	0.9	57
68	Outcome measures for primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2012, 39, 97-102.	6.5	46
69	Biologic treatments in Sjögren's syndrome. <i>Presse Medicale</i> , 2012, 41, e495-e509.	1.9	14
70	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
71	United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. <i>Rheumatology</i> , 2011, 50, 32-39.	1.9	64
72	Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 500-507.	0.9	192

#	ARTICLE	IF	CITATIONS
73	Biological therapies in primary Sjögren's syndrome. Expert Opinion on Biological Therapy, 2011, 11, 921-936.	3.1	8
74	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care and Research, 2010, 62, 551-558.	3.4	66
75	Estimating Indirect Costs in Primary Sjögren's Syndrome. Journal of Rheumatology, 2010, 37, 1010-1015.	2.0	42
76	Primary Sjogren's syndrome: too dry and too tired. Rheumatology, 2010, 49, 844-853.	1.9	119
77	Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1731-1732.	0.9	31
78	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1103-1109.	0.9	734
79	Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health and Quality of Life Outcomes, 2009, 7, 46.	2.4	177
80	Patient-Reported Outcomes Including Fatigue in Primary Sjögren's Syndrome. Rheumatic Disease Clinics of North America, 2008, 34, 949-962.	1.9	25
81	Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. Journal of Rheumatology, 2005, 32, 143-9.	2.0	21
82	The development and initial validation of the Liverpool sicca index to assess symptoms and dysfunction in patients with primary Sjögren's syndrome. Journal of Oral Pathology and Medicine, 2003, 32, 154-162.	2.7	13
83	The assessment of fatigue in primary Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2003, 32, 33-37.	1.1	40
84	Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. Journal of Rheumatology, 2003, 30, 1259-66.	2.0	56
85	Candidate T cell epitopes of the human La/SSB autoantigen. Arthritis and Rheumatism, 2002, 46, 209-214.	6.7	27
86	Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis and Rheumatism, 2001, 44, 2633-2641.	6.7	264
87	Scleritis as the presenting sign of primary antiphospholipid syndrome. Eye, 2001, 15, 558-559.	2.1	8
88	Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. , 2001, 44, 2633.		1
89	215. Cognitive Impairment in Primary Sjögren's Syndrome. Rheumatology, 0, , .	1.9	0
90	1115 Trials and Tribulations of B Cell Therapies (Tractiss). Rheumatology, 0, , .	1.9	0